Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor–Resistant Disease

Cited by (480)

Items 301–400 of 480

1. Phase II Study of the EGFR-TKI Rechallenge With Afatinib in Patients With Advanced NSCLC Harboring Sensitive EGFR Mutation Without T790M: Okayama Lung Cancer Study Group Trial OLCSG 1403
   Naohiro Oda, Eiki Ichihara, Katsuyuki Hotta, Kiichiro Ninomiya, Takashi Ninomiya, Toshio Kubo, Daisuke Minami, Toshi Murakami, Toshihide Yokoyama, Daijiro Harada et al. · 2016 · Clinical Lung Cancer
2. A phase 1b/2 study of PF-06747775 as monotherapy or in combination with Palbociclib in patients with epidermal growth factor receptor mutant advanced non-small cell lung cancer
   Byoung Chul Cho, Sarah B. Goldberg, Dong‐Wan Kim, Mark A. Socinski, Timothy Francis Burns, Zarnie Lwin, Nuzhat Pathan, Dong Wei, Joanna C. Masters, Nandini Cossons et al. · 2022 · Expert Opinion on Investigational Drugs
3. Integrated genomic approaches identify upregulation of SCRN1 as a novel mechanism associated with acquired resistance to erlotinib in PC9 cells harboring oncogenic EGFR mutation
   Nayoung Kim, Ahye Cho, Hideo Watanabe, Yoon‐La Choi, Meraj Aziz, Michelle Kassner, Je‐Gun Joung, Angela Kyung-Joo Park, Joshua M. Francis, Joon Seol Bae et al. · 2016 · Oncotarget
4. A platinum-based hybrid drug design approach to circumvent acquired resistance to molecular targeted tyrosine kinase inhibitors
   Yuming Wei, Daniel C. Poon, Rong Fei, Amy S. M. Lam, Steve C. F. Au‐Yeung, Kenneth K.W. To · 2016 · Scientific Reports
5. Delivery of gefitinib with an immunostimulatory nanocarrier improves therapeutic efficacy in lung cancer
   Dingwei Diao, Jianxue Zhai, Jianjun Yang, Hua Wu, Jianjun Jiang, Xiaoying Dong, Antonio Passaro, Beatrice Aramini, Shuan Rao, Kaican Cai · 2021 · Translational Lung Cancer Research
6. Mapping inhibitor response to the in-frame deletions, insertions and duplications of epidermal growth factor receptor (EGFR) in non-small cell lung cancer
   Jingheng Ning, Qi Wu, Zhenguo Liu, Jianhui Wang, Xianfu Lin · 2015 · Journal of Receptors and Signal Transduction
7. Investigating mutation-specific biological activities of small molecules using quantitative structure-activity relationship for epidermal growth factor receptor in cancer
   P. Anoosha, Ramasamy Sakthivel, M. Michael Gromiha · 2017 · Mutation research. Fundamental and molecular mechanisms of mutagenesis
8. Discovery of N-aryl-N′-pyrimidin-4-yl ureas as irreversible L858R/T790M mutant selective epidermal growth factor receptor inhibitors
   Fusheng Zhou, Liang Zhang, Yun-Zhou Jin, Wei Liu, Pengfei Cheng, Xiangyu He, Jing Xie, Sida Shen, Lei Jing, Haixia Ji et al. · 2017 · Bioorganic & Medicinal Chemistry Letters
9. RNA methylation of CD47 mediates tumor immunosuppression in EGFR-TKI resistant NSCLC
   Wei Zhang, Jiawen Wang, Jialu Liang, Zhanghai He, Kefeng Wang, Huayue Lin · 2025 · British Journal of Cancer
10. Risk of interstitial lung disease in non-small cell lung cancer treated with EGFR-TKI: a real-world pharmacovigilance study
    Miao Xu, Yuan Liu, Xiaoqin Li, Rong Zhao · 2025 · Frontiers in Pharmacology
11. Readministration of EGFR Tyrosine Kinase Inhibitor in Non-small Cell Lung Cancer Patients after Initial Failure, What Affects its Efficacy?
    Ze-Rui Zhao, Wěi Li, Hao Long · 2014 · Scientific Reports
12. Lung Cancer Genomics in the Era of Accelerated Targeted Drug Development
    Priyanga Wijesinghe, Aliccia B. Bollig-Fischer · 2015 · Advances in experimental medicine and biology
13. Survival of Asian Females With Advanced Lung Cancer in the Era of Tyrosine Kinase Inhibitor Therapy
    Daniel Jacob Becker, Juan P. Wisnivesky, Michael L. Grossbard, Abraham Chachoua, D. Ross Camidge, Benjamin Philip Levy · 2016 · Clinical Lung Cancer
14. Association of BIM Deletion Polymorphism and BIM-γ RNA Expression in NSCLC with EGFR Mutation
    Kazutoshi Isobe, Atsushi Kakimoto, TETSUO MIKAMI, Kyohei Kaburaki, Hiroshi Kobayashi, TAKAHIRO YOSHIZAWA, TAKASHI MAKINO, HAJIME OTSUKA, Go Sano, Keishi Sugino et al. · 2016 · Cancer Genomics & Proteomics
15. Early 18F-FDG uptake as a reliable imaging biomarker of T790M-mediated resistance but not MET amplification in non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors
    Viviana De Rosa, Francesca Iommelli, Marcello Monti, Ciro Gabriele Mainolfi, Rosa Fonti, Silvana Del Vecchio · 2016 · EJNMMI Research
16. Identification of Novel EGFR Inhibitors for the Targeted Therapy of Colorectal Cancer Using Pharmacophore Modelling, Docking, Molecular Dynamic Simulation and Biological Activity Prediction
    Amrutha Krishnan K, Sudha George Valavi, Amitha Joy · 2024 · Anti-Cancer Agents in Medicinal Chemistry
17. Questionnaire survey on patient awareness of invasive rebiopsy in advanced non‐small cell lung cancer
    Tomoya Fukui, Mikiko Ishihara, Masashi Kasajima, Yasuhiro Hiyoshi, Yoshiro Nakahara, Sakiko Otani, Satoshi Igawa, Masanori Yokoba, Hisashi Mitsufuji, Masaru Kubota et al. · 2019 · Thoracic Cancer
18. A novel osimertinib-resistant human lung adenocarcinoma cell line harbouring mutant EGFR and activated IGF1R
    Go Makimoto, Kiichiro Ninomiya, Toshio Kubo, Ryota Sunami, Yuka Kato, Eiki Ichihara, Kadoaki Ohashi, Kammei Rai, Katsuyuki Hotta, Masahiro Tabata et al. · 2021 · Japanese Journal of Clinical Oncology
19. Present standards and future perspectives in the treatment of metastatic non-small cell lung cancer
    Stefan Zimmermann, Solange Peters · 2015 · Cancer and Metastasis Reviews
20. Systematic bioinformatic approaches reveal novel gene expression signatures associated with acquired resistance to EGFR targeted therapy in lung cancer
    Marjan Mojtabavi Naeini, Manoochehr Tavassoli, Kamran Ghaedi · 2018 · Gene
21. Phase I study of TAS-121, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with non-small-cell lung cancer harboring EGFR mutations
    Makoto Nishio, Haruyasu Murakami, Yuichiro Ohe, Toyoaki Hida, Hiroshi Sakai, Kazuo Kasahara, Fumio Imamura, Tomohisa Baba, Kaoru Kubota, Yukio Hosomi et al. · 2019 · Investigational New Drugs
22. Plasmodium Circumsporozoite Protein Enhances the Efficacy of Gefitinib in Lung Adenocarcinoma Cells by Inhibiting Autophagy via Proteasomal Degradation of LC3B
    Xiao Lu, Jiao Zhang, Yanqi Li, Quanxing Liu, Dong Zhou, Xu‐Feng Deng, Yuan Qiu, Qian Chen, Manyuan Li, Xiao-Qing Liu et al. · 2022 · Frontiers in Cell and Developmental Biology
23. Second-Line Treatment Options in Non–Small-Cell Lung Cancer: Report From an International Experts Panel Meeting of the Italian Association of Thoracic Oncology
    Cesare Gridelli, Paul Baas, Fabrice Barlési, Fortunato Ciardiello, Lucio Crinò, Enriqueta Felip, Shirish M. Gadgeel, Vali Papadimitrakopoulou, Luis G Paz-Ares, David Planchard et al. · 2017 · Clinical Lung Cancer
24. Concordance of epidermal growth factor receptor mutation detection in bodily fluids other than blood with tissue biopsy: A retrospective analysis
    Anuradha Chougule, Priyanka Pange, Shrutika Kale, Vinita Jagtap, Kavya Nambiar, Ankita Nikam, Priyanka Tiwrekar, Vaishakhi Trivedi, Vichitra Behel, Akhil Kapoor et al. · 2020 · Cancer Research Statistics and Treatment
25. Epithelial-mesenchymal transition is associated with osteopontin-induced EGFR-TKI resistance in EGFR mutant non-small cell lung cancer
    Junjie Chen, Lin Shi, Qian Yao, Yi Jin, Nian Dong, Chengshui Chen, Beibei Wang · 2023 · Journal of Thoracic Disease
26. Successful Desensitization Treatment with Osimertinib after the Development of Osimertinib-induced Urticaria in a Patient Undergoing Treatment for Non-small Cell Lung Cancer Harboring the EGFR T790M Mutation
    Go Makimoto, Tatsuya Nishi, Keita Kawakado, Tomoka Nishimura, Tomoki Tamura, Kenichiro Kudo, Shoichi Kuyama · 2020 · Internal Medicine
27. Integrated histological and molecular analyses of rebiopsy samples at osimertinib progression improve post-progression survivals: A single-center retrospective study
    Jiangtao Cheng, Yihui Yao, Yu-Er Gao, Shiling Zhang, Hua‐Jun Chen, Zhen Wang, Hong‐Hong Yan, Qing Hua Zhou, Hai‐Yan Tu, Xu‐Chao Zhang et al. · 2020 · Lung Cancer
28. Everolimus prolonged survival in transgenic mice with EGFR-driven lung tumors
    Yasugi, Masayuki, Takigawa, Nagio, Ochi, Nobuaki, Ohashi, Kadoaki, Harada, Daijiro, Ninomiya, Takashi, Murakami, Toshi, Honda, Yoshihiro, Ichihara, Eiki, Tanimoto, Mitsune et al. · 2014 · Experimental Cell Research
29. Impact of coexisting gene mutations in EGFR-mutated non–small cell lung cancer before treatment on EGFR T790M mutation status after EGFR-TKIs
    Masayuki Takeda, Kazuko Sakai, Hidetoshi Hayashi, Kaoru Tanaka, Koji Haratani, Takayuki Takahama, Ryoji Kato, Kimio Yonesaka, Kazuto Nishio, Kazuhiko Nakagawa · 2019 · Lung Cancer
30. Real-world efficacy of osimertinib in previously EGFR-TKI treated NSCLC patients without identification of T790M mutation
    Yung‐Hung Luo, Han Liu, Jason A. Wampfler, Henry D. Tazelaar, Yalun Li, Tobias Peikert, Dan Liu, Konstantinos Leventakos, Yuh-Min Chen, Yanan Yang et al. · 2021 · Journal of Cancer Research and Clinical Oncology
31. Treatment paradigms in advanced non-small-cell lung cancer.
    Caroline Elizabeth McCoach, Karen L. Kelly · 2013 · PubMed
32. The significance of plasma high density lipoprotein cholesterol (hdlc).
    Suprita Gupta, Ganapathy Rajagopal · 2007 · PubMed
33. Overcoming EGFR‐Mediated Dendritic Cell Dysfunction to Enhance Anti‐tumor Immunity in EGFR‐Mutant NSCLC by Precisely Targeting CD73 With pH‐responsive Nanocarriers
    Xiaoling Shang, Xudong Geng, Zixu Wang, Shumin Yuan, Shanshan Ding, Geoffrey Liu, Xinchun Ma, Xuan Sun, Huimin Wang, Ying Hao Sun et al. · 2025 · Advanced Science
34. Lung adenocarcinoma surfaceome remodeling with EGFR inhibitors uncovers placental alkaline phosphatase as a target for combination therapy
    Yihui Chen, Rongzhang Dou, M J Hong, Hanwen Xu, Jody Vykoukal, Ricardo A. Léon-Letelier, Yining Cai, Soyoung Park, Ehsan Irajizad, Fu Chung Hsiao et al. · 2025 · Cell Reports Medicine
35. Co-expression of receptor tyrosine kinases and CD8 T-lymphocyte genes is associated with distinct prognoses, immune cell infiltration patterns and immunogenicity in cancers
    Junyu Long, Peipei Chen, Xiaobo Yang, Jin‐Song Bian, Yang Xu, Anqiang Wang, Yu Syuan Lin, Hanping Wang, Xinting Sang, Haitao Zhao · 2022 · Translational research
36. Clinical characteristics of patients treated with immune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer: CS-Lung-003 prospective observational registry study
    Tadahiro Kuribayashi, Kadoaki Ohashi, Kazuya Nishii, Kiichiro Ninomiya, Yukari Tsubata, Nobuhisa Ishikawa, Masahiro Kodani, Nobuhiro Kanaji, Masahiro Yamasaki, Kazunori Fujitaka et al. · 2024 · Journal of Cancer Research and Clinical Oncology
37. Association of Carbonic Anhydrase 9 Polymorphism and the Epithelial Growth Factor Receptor Mutations in Lung Adenocarcinoma Patients
    Ya‐Yen Yu, Hui‐Ling Chiou, Shih‐Ming Tsao, Chen-Cheng Huang, Chih‐Yun Lin, Chia‐Yi Lee, Thomas Chang Yao Tsao, Shun‐Fa Yang, Yi-Wen Huang · 2020 · Diagnostics
38. Discovery and optimization of covalent EGFR T790M/L858R mutant inhibitors
    Niels Hoogenboom, Dennis Demont, Edwin de Zwart, Saskia Verkaik, Maaike Emmelot-van Hoek, Bas van de Kar, Allard Kaptein, Tjeerd A. Barf · 2021 · Bioorganic & Medicinal Chemistry Letters
39. Chronic nicotine exposure affects programmed death-ligand 1 expression and sensitivity to epidermal growth factor receptor-tyrosine kinase inhibitor in lung cancer
    Chang Dong Yeo, In Kyoung Kim, Woo Ho Ban, Hye Seon Kang, Jin Woo Kim, Seung Joon Kim, Jong Y. Park, Sang Haak Lee · 2019 · Translational Cancer Research
40. Orthogonal threading‐through‐β‐sheet design of lung cancer EGFR extracellular domain‐derived peptidic mimotopes binding to anti‐EGFR antibody
    X Zhang, Na Chang, Xian‐Qi Zhang · 2022 · Chemical Biology & Drug Design
41. EGFR TKI resistance in lung cancer cells using RNA sequencing and analytical bioinformatics tools
    Mark Howell, Ryan J. Green, Junior Cianne, Guy W. Dayhoff, Vladimir Nikolaevich Uversky, Shyam S. Mohapatra, Subhra Mohapatra · 2022 · Journal of Biomolecular Structure and Dynamics
42. Overcoming resistance to first generation EGFR TKIs with cetuximab in combination with chemotherapy in an EGFR mutated advanced stage NSCLC patient
    Andreas Pircher, Claudia Manzl, Michael Fiegl, Helmut Popper, Robert Pirker, Wolfgang Hilbe · 2013 · Lung Cancer
43. Indian consensus statement for treatment of advanced non small cell lung cancer: First line, maintenance, and second line
    Indian Cooperative Oncology Network (ICON) · 2017 · Indian Journal of Cancer
44. Technical Validation and Clinical Implications of Ultrasensitive PCR Approaches for EGFR-Thr790Met Mutation Detection in Pretreatment FFPE Samples and in Liquid Biopsies from Non-Small Cell Lung Cancer Patients
    Javier Simarro, Gema Pérez-Simó, Nuria Mancheño, Emilio Ansótegui, Carlos Francisco Muñoz-Núñez, José Gómez‐Codina, Óscar Juan, Sarai Palanca · 2022 · International Journal of Molecular Sciences
45. Heuristic value-based framework for lung cancer decision-making
    Isa Mambetsariev, Rebecca R. Pharaon, Arin Nam, Kevin Knopf, Benjamin Djulbegović, Victoria Meucci Villaflor, Everett E. Vokes, Ravi Salgia · 2018 · Oncotarget
46. Reuse of osimertinib after small cell lung cancer transformation in lung adenocarcinoma with de-novo epidermal growth factor receptor T790M mutation: case report
    Xiuwen Wang, Jizhen Liang, Li Li, Zhaojun Pan, Lin Wang · 2022 · Anti-Cancer Drugs
47. The potential role of extracellular regulatory kinase in the survival of patients with early stage adenocarcinoma.
    Simone de Leon Martini, Carolina Beatriz Müller, Rosalva T. Meurer, Marilda da Cruz Fernandes, Rodrigo Coutinho Mariano, Mariel Barbachan e Silva, Fábio Klamt, C Andrade · 2014 · PubMed Central
48. Therapeutic Drug Monitoring of Imatinib and N‐Desmethyl Imatinib in Chronic Myeloid Leukemia Patients Using LC‐MS/MS in a Cohort Study
    Xiaoxing Huang, Yiwei Liu, Jie Chen, Heng Zheng, Yufeng Ding, Zheng He · 2023 · The Journal of Clinical Pharmacology
49. „Liquid biopsy“: Analyse molekularer Marker aus Blutproben zur Therapiesteuerung beim Lungenkarzinom
    Wolfgang Michael Brueckl, Ralph Markus Wirtz, Tobias Bertsch, Joachim Hans Ficker, Andreas Jung · 2017 · Pneumologie
50. Pulmonary Adenocarcinoma—Pathology and Molecular Testing
    Prodipto Pal, Michael Cabanero, Ming‐Sound Tsao · 2018 · Elsevier eBooks
51. Molekulardiagnostik des nichtkleinzelligen Lungenkarzinoms
    Arne Warth, Volker Endris, Mark Kriegsmann, Albrecht Stenzinger, Roland Penzel, Nicole Pfarr, Wilko Weichert · 2015 · Der Pathologe
52. Triple therapy with osimertinib, bevacizumab and cetuximab in EGFR‑mutant lung cancer with HIF‑1α/TGF‑α expression
    Kazuya Nishii, Kadoaki Ohashi, Hiromi Watanabe, Go Makimoto, Takamasa Nakasuka, Hisao Higo, Kiichiro Ninomiya, Yuka Kato, Toshio Kubo, Kammei Rai et al. · 2021 · Oncology Letters
53. Evaluating Synergistic Effects of miR-34a Mimics in Combination with Other Therapeutic Agents in Cultured Non-Small Cell Lung Cancer Cells
    Jane Y. Zhao, Andreas G. Bader · 2016 · Methods in molecular biology
54. A novel multi-target inhibitor harboring selectivity of inhibiting EGFR T790M sparing wild-type EGFR.
    Xiaoping Song, Xin Qi, Qiang Wang, Weiming Zhu, Jing Li · 2017 · Europe PMC (PubMed Central)
55. Leveraging Genomic Factors to Improve Benefit–Risk
    Robert N. Schuck, Rosane Charlab, GM Blumenthal · 2017 · Clinical and Translational Science
56. Regulation of post-translational modification of PD-L1 and associated opportunities for novel small-molecule therapeutics
    Jinglin Tang, Han Liu, Jinze Li, Yibo Zhang, Suyang Yao, Kan Yang, Zhi‐Hao You, Xiaoqiang Qiao, Yali Song · 2024 · Future Medicinal Chemistry
57. SOS1 inhibition suppresses the emergence of osimertinib resistance to generate a durable response in EGFR -mutant lung cancer
    Brianna R. Daley, Patricia L. Theard, Jacob M. Hughes, Bridget A. Finniff, Marco H. Hofmann, Kaja Kostyrko, Robyn L. Schenk, Heidi M. Vieira, James W. Askew, Robert E. Lewis et al. · 2025 · Science Signaling
58. Effectiveness and safety of afatinib, gefitinib, and erlotinib for treatment-naïve elderly patients with epidermal growth factor receptor-mutated advanced non-small-cell lung cancer: a multi-institute retrospective study
    Ling‐Jen Hung, Ping‐Chih Hsu, Cheng‐Ta Yang, Chih‐Hsi S. Kuo, John Wen‐Cheng Chang, Chen‐Yang Huang, Ching‐Fu Chang, Chiao‐En Wu · 2024 · Aging
59. Erlotinib Salvage Therapy in Pulmonary Adenocarcinoma Patients With Disease Progression After Previous EGFR-TKI Treatment
    Wen-Shuo Wu, Chieh‐Hung Wu, Shinn‐Liang Lai, Chao‐Hua Chiu, Jen-Fu Shih, Yu‐Chin Lee, Yuh‐Min Chen · 2014 · American Journal of Clinical Oncology
60. A Novel and Efficient Synthesis of Anti-Cancer Agent, Mereletinib
    Haidong Liu, Yong-Feng Lv, Yuan Li, Jin Cai, Junqing Chen, Qin Yu, Min Ji · 2015 · Journal of Chemical Research
61. Dynamics of Plasma EGFR T790M Mutation in Advanced NSCLC: A Multicenter Study
    Zhengquan Yang, Jialu Li, Yujie Hu, Meihua Chen, Danli Peng, Dan Zong, Qingjuan Shang, Lianqin Tao, Yanling Zhao, Yiyun Ni et al. · 2019 · Targeted Oncology
62. Macrophage renewal modes affect acquired resistance to gefitinib in EGFR‑mutant lung cancer PC‑9 cells
    Bao-Xia Zhao, Yan Zhang, Lu Shen, Mei Li · 2022 · Oncology Reports
63. Clonality Analysis for the Relationship between the Pulmonary Combined Neuroendocrine Carcinoma and “the So-Called Reported Histologic Transformation”
    Haiyue Wang, Yanli Zhu, Wei Sun, Xin Yang, Xinying Liu, Kaiwen Chi, Xiaozheng Huang, Lixin Zhou, Weijing Cai, Dongmei Lin · 2023 · Cancers
64. It might be a dead end: immune checkpoint inhibitor therapy in EGFR-mutated NSCLC
    Ken Akao, Yuko Oya, Takaya Sato, Aki Ikeda, Tomoya Horiguchi, Yasuhiro Gotô, Naozumi Hashimoto, Masashi Kondo, Kazuyoshi Imaizumi · 2024 · Exploration of Targeted Anti-tumor Therapy
65. From academia to industry: a road more travelled
    William J. Pao · 2017 · Annals of Oncology
66. Molecular Diagnosis and Targeting for Lung Cancer
    Kazue Yoneda, Fumihiro Tanaka · 2017 · Current human cell research and applications
67. An Improved Process for the Preparation of a Covalent Kinase Inhibitor through a C–N Bond-Forming SNAr Reaction
    Andrew T. Parsons, Michele Kubryk, Simon J. Hedley, Oliver R. Thiel, David Bauer, Matthew S. Potter, Zhenxin Lin · 2018 · Organic Process Research & Development
68. Detection of epidermal growth factor receptor mutations in exhaled breath condensate using droplet digital polymerase chain reaction
    Kazuya Nishii, Kadoaki Ohashi, Tomoki Tamura, Kiichiro Ninomiya, Takehiro Matsubara, Satoru Senoo, Hirohisa Kano, Hiromi Watanabe, Naohiro Oda, Go Makimoto et al. · 2020 · Oncology Letters
69. Radiosensitizers in pancreatic cancer—Preclinical and clinical exploits with molecularly targeted agents
    Amanda J. Walker, Sara Rachel Alcorn, Amol Kumar Narang, Katriana M. Nugent, Aaron Tyler Wild, Joseph M. Herman, Phuoc Tho Tran · 2013 · Current Problems in Cancer
70. Anti PD-L1 combined with other agents in non-small cell lung cancer: combinations with non-immuno-oncology agents
    Sonam Puri, Monica Sheila Chatwal, Jhanelle E Gray · 2017 · Expert Review of Respiratory Medicine
71. Epidermal growth factor receptor (EGFR) mutation testing, from bench to practice: a single institute experience.
    Hassan Shikhrakab, Yasir Y. Elamin, Cathal P. O’Brien, Kathy A. Gately, Stephen P. Finn, Kenneth John O'Byrne, Nemer Osman · 2014 · PubMed
72. The Usefulness of Nanotechnology in Improving the Prognosis of Lung Cancer
    Gabriela Bordeianu, Nina Filip, Andrei Tudor Cernomaz, Bogdan Veliceasa, Loredana Liliana Hurjui, Alin Constantin Pînzariu, Mihaela Perțea, Andreea Clim, Mihai Vasile Marinca, Ionela Lăcrămioara Șerban · 2023 · Biomedicines
73. Efficacy and safety of anti-programmed cell death protein 1 antibody combination therapy in patients with advanced experienced epidermal growth factor receptor-tyrosine kinase inhibitor-resistant lung adenocarcinoma: a retrospective cohort study
    Chang Wan, Yiruo Zhang, Pingping Liu, Xinkuan Mei, Gang Cheng, Jingdan Pang, Sheng Chen, Jianping Xu, Jyoti Dhar Malhotra, Hesheng Qian et al. · 2023 · Journal of Thoracic Disease
74. EGFR Signaling and its inhibition by EGFR inhibitors in NSCLC
    Rajvi Patel · 2014 · International Journal of Applied Sciences and Biotechnology
75. Pharmacodynamic modelling of resistance to epidermal growth factor receptor inhibition in brain metastasis mouse models
    Emma C. Martin, Leon J Aarons, James W.T. Yates · 2018 · Cancer Chemotherapy and Pharmacology
76. Leukocyte Telomere Length and Clinical Outcomes of Advanced Lung Adenocarcinoma Patients with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Treatment
    Ji Li, Li Zhang, Hui Zhu, Wenting Pan, Nasha Zhang, Yankang Li, Ming Yang · 2018 · DNA and Cell Biology
77. The EGFR and KRAS Mutation Status and Correlations with the Prevalence of Bone Metastases - The Results of Three Year Retrospective Analysis
    Zoltán Balikó · 2014 · Journal of Carcinogenesis & Mutagenesis
78. Molecular Testing in Lung Cancer
    Carolyn Jane Shiau, Ming‐Sound Tsao · 2016 · Elsevier eBooks
79. Disease flare after discontinuing gefitinib in a patient with lung adenocarcinoma and concomitant epithelial growth factor receptor mutation and anaplastic lymphoma kinase translocation
    Eun Hye Park, Hwa Young Lee, Jin Woo Kim, Chang Dong Yeo · 2017 · Journal of Thoracic Disease
80. Fine-needle aspiration of small pulmonary nodules yields material for reliable molecular analysis of adenocarcinomas
    Dianne E. Grunes, David F. Yankelevitz, Mary Beth Beasley, David E Burstein, David Zhang, Fei Ye, Arnold H. Szporn, Qiusheng Si, Zesong Zhang, Fadi E. Salem et al. · 2015 · Journal of the American Society of Cytopathology
81. Systematic profiling of ATP response to acquired drug-resistant EGFR family kinase mutations
    Dingwa Zhang, Deyong He, Xiaoliang Pan, Lijun Liu · 2020 · Journal of the Serbian Chemical Society
82. Stratification of non-small cell lung adenocarcinoma patients with EGFR actionable mutations based on drug-resistant stem cell genes
    Xiaohong Xie, Lifeng Li, Liang Xie, Zhentian Liu, Guoliang Zhang, Xuan Gao, Wenying Peng, Haiyi Deng, Yilin Yang, Meiling Yang et al. · 2023 · iScience
83. Immunotherapy for patients with EGFR-TKI-resistant non-small-cell lung cancer: Potential mechanisms, efficacy predictors, and therapeutic integration
    Xinwei Wu, Yangbin Shi, Danni Wang, Beibei Liu, Yanwei Zhang, Lele Zhang, Fangfei Qian, Wei Zhang · 2026 · Chinese Medical Journal - Pulmonary and Critical Care Medicine
84. Case Report: Olaparib combined with temozolomide and atezolizumab in a case of BRCA2-mutated small-cell transformation of lung adenocarcinoma
    Meiyuan Liu, Pei Gao, Fu Liu, Deng Li, Yanqi Wang, Juan Yu · 2026 · Frontiers in Oncology
85. Mutation de l’EGFR, de l’étude du gène à la pratique clinique : exemplarité ou exception ?
    Jacques L. Cadranel, Perrine Créquit, Anne-Marie Ruppert, A. Lavolé, Valérie Gounant, Roger Lacave, Jocelyne Fleury‐Feith, Martine Antoine, Marie Wislez · 2013 · Revue des Maladies Respiratoires Actualités
86. [Progress of Immunotherapy in EGFR-mutated Advanced Non-small Cell Lung Cancer].
    Yaoyao Liu, Jianlong Miao · 2024 · PubMed Central
87. Rare case report: a case of histological type transformation of lung cancer caused by neoadjuvant immunotherapy
    Quanqing Li, Guangxin Zhang, Hao Yang, Jindong Li · 2024 · Frontiers in Oncology
88. Exploration of novel quinoline derivatives: Anticancer potential revealed through design, synthesis and biological evaluation
    Janaiah Chevula, Saikrishna Balabadra, Ramakrishna Munnaluri, Vijjulatha Manga · 2025 · Journal of Chemical Sciences
89. A novel diagnostic system to evaluate epidermal growth factor receptor impact as a prognostic and therapeutic indicator for lung adenocarcinoma
    Kazuya Takakuwa, Kaoru Mogushi, Min Ji Han, Tomoaki Fujii, Masaki Hosoya, Arina Yamanami, Tomomi Akita, Chikamasa Yamashita, Tetsu Hayashida, Shunsuke Kato et al. · 2020 · Scientific Reports
90. Diffuse Hemorrhagic Brain Metastases in an ALK Fusion Positive Patient on Crizotinib
    Kevin Jao, Pascale Tomasini, Catherine Labbé, Mark K. Doherty, Frances A. Shepherd · 2015 · Journal of Thoracic Oncology
91. Excellent platinum dependent response to chemotherapy after relapse under TKI treatment in NSCLC with sensitizing EGFR mutations and no detectable resistance mutations: three case studies
    Diego Erich Kauffmann-Guerrero, Zulfiya Syunyaeva, Kathrin Kahnert, Amanda Tufman · 2019 · AME Case Reports
92. Phytochemical based sestrin2 pharmacological modulators in the treatment of adenocarcinomas
    Abdullahi Opeyemi Alausa, Ugwu Chukwuebuka Victor, Ugwu Obiora Celestine, Ismail Abiodun Eweje, Toheeb Adewale Balogun, Rofiat Oluwabusola Adeyemi, Mercy Olatinwo, Abdeen Tunde Ogunlana, Oladapo O. Oladipo, Barakat Olaleke · 2021 · Phytomedicine Plus
93. Molecular Testing in Lung Cancer
    Céline Mascaux, Ming‐Sound Tsao, Fred R. Hirsch · 2018 · Elsevier eBooks
94. T790M and Acquired Resistance of Epidermal Growth Factor Receptor to Tyrosine Kinase Inhibitors in Patients with Lung Adenocarcinoma.
    Hanifeh Mirtavoos‐Mahyari, Azizollah Abbasi Dezfouli, Zahra Esfahani‐Monfared, Adnan Khosravi, Sharareh Seifi, Kambiz Sheikhy · 2022 · PubMed Central
95. Droplet Digital PCR as a Molecular Tool for the Detection of the EGFR T790M Mutation in NSCLC Patients with the EGFR Activating Mutations
    Selma Durgut, Lana Salihefendić, Dino Pećar, Ivana Čeko, Naida Mulahuseinović, Midhat Izmirlija, Rijad Konjhodžić · 2023 · Balkan Journal of Medical Genetics
96. Clinical Response to Everolimus of EGFR–Mutation-Positive NSCLC With Primary Resistance to EGFR TKIs
    Hiromichi Matsuoka, Hiroyasu Kaneda, Kazuko Sakai, Atsuko Koyama, Kazuto Nishio, Kazuhiko Nakagawa · 2016 · Clinical Lung Cancer
97. Biology of Lung Cancer
    Pierre P. Massion, Lecia Van Dam Sequist, William J. Pao · 2015 · Elsevier eBooks
98. Comparing survival and treatment response of patients with acquired T790M mutation second‐line osimertinib versus sequential treatment of chemotherapy followed by osimertinib: A real‐world study
    Chin‐Chou Wang, Chien‐Hao Lai, Yu‐Ping Chang, Huang‐Chih Chang, Chia‐Cheng Tseng, Kuo‐Tung Huang, Meng‐Chih Lin · 2021 · Thoracic Cancer
99. A new single-cell level R-index for EGFR-TKI resistance and survival prediction in LUAD
    Xiaohong Xie, Lifeng Li, Liang Xie, Zhentian Liu, Xuan Gao, Xuefeng Xia, Haiyi Deng, Yilin Yang, Meiling Yang, Lianpeng Chang et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
100. Two Distinct Primary EGFR-Mutated Lung Adenocarcinoma Within the Same Patient: A Case Report
     Junid A. Naveed Ahmad, Bowen He, Brett Schroeder, Joseph Rosales · 2022 · International Journal of Cancer Care and Delivery